QC Laboratory Deviations

Managing QC Laboratory Deviations in Pharmaceutical Quality Systems

A QC laboratory deviation refers to any departure from approved methods, specifications, SOPs, or Good Laboratory Practices (GLP) during analytical testing, documentation, or result interpretation. These deviations can include equipment…

QC Lab Deviations Like OOS? Investigation Workflow and Fixes

The first step in recognizing QC laboratory deviations is identifying the symptoms or signals that trigger an investigation. Commonly observed symptoms include:Click to read the full article.

Unauthorized method modification during stability analysis – CAPA failure exposed

Upon routine compliance checks, a laboratory analyst observed deviations in the stability results of an important product. Specific signals included:Click to read the full article.

Backdated test records during method transfer – data integrity breach analysis

The initial identification of issues begins in the QC lab. In this case, the alarm was raised by a laboratory technician who noticed inconsistencies between the recorded data for method…

OOS invalidated without justification during investigation – CAPA failure exposed

The initial sign of the issues at hand came when the quality control (QC) laboratory received test results indicating that a batch of solid dosage forms had failed the dissolution…

System suitability failure ignored during method transfer – CAPA failure exposed

In this case, symptoms of a system suitability failure became evident as laboratory personnel began executing planned method transfers. The following signals were observed:Click to read the full article.

Unapproved chromatographic integration during stability analysis – inspection citation explained

The initial signs of an unapproved chromatographic integration often appear during the routine review of stability analysis data. Symptoms may include:Click to read the full article.

Unauthorized method modification during FDA inspection – inspection citation explained

The initial symptoms that led to the discovery of the unauthorized method modification included:Click to read the full article.

Unapproved chromatographic integration during method transfer – CAPA failure exposed

In this case, the issue was first flagged by laboratory analysts who noticed discrepancies between chromatographic results during method transfer from R&D to QC labs. Key symptoms included:Click to read…

System suitability failure ignored during stability analysis – data integrity breach analysis

The initial indicator of a potential system suitability failure was an inconsistency in the chromatographic data generated during the stability analysis of a novel pharmaceutical product. Operators noticed that the…

Unauthorized method modification during data review – regulatory enforcement risk

During routine quality control data review, unexpected results were flagged by QC analysts. These results deviated from validated analytical method specifications, raising immediate concerns about data integrity and method compliance.…

Sample preparation error during FDA inspection – CAPA failure exposed

During a routine FDA inspection, several indicators prompted further scrutiny of the laboratory’s sample preparation processes. Observers noted discrepancies in sample concentrations when compared with established reference standards. Specifically, the…